Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 181 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Prostatic Neoplasm Phase2 Canada
China
Czechia
France
Italy
Korea, Republic of
Netherlands
Poland
Singapore
Spain
United States
View All

A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)

Lupus Erythematosus, Systemic, Lupus Nephritis Phase2 France
Germany
Japan
Singapore
Spain
United States
View All

Secukinumab Open Label Roll-over Extension Protocol

Autoimmunity, Inflammation Phase4 Brazil
Bulgaria
China
Colombia
Czechia
Guatemala
India
Poland
Russian Federation
South Africa
Spain
Switzerland
United States
View All

Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT

Prostate Cancer Phase1, Phase2 Australia
France

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis Phase4 Taiwan

Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care

Heart Failure Germany

Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission

Giant Cell Arteritis Phase3 Germany

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Ovarian Cancer, Lung Cancer Phase1 Israel

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria Phase3 Argentina
Canada
China
Germany
Hong Kong
Italy
Japan
Malaysia
Netherlands
Poland
Singapore
South Africa
Spain
Thailand
Turkey
United Kingdom
United States
View All

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Lupus Nephritis Phase3 Argentina
Brazil
Canada
Chile
China
Colombia
Czechia
Estonia
France
Germany
Guatemala
Hong Kong
Hungary
India
Italy
Korea, Republic of
Lithuania
Malaysia
Mexico
Romania
Singapore
Spain
Taiwan
Thailand
United Kingdom
United States
Vietnam
View All